GU Cancers 2023 | What’s on the horizon for adjuvant therapies for RCC?

Matthew R. Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses a current investigation into pembrolizumab plus belzutifan for patients with renal cell carcinoma (RCC) and emphasises the importance of using biomarkers to improve patient selection for certain treatments. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.